as 04-01-2025 4:00pm EST
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Founded: | 2005 | Country: | United States |
Employees: | N/A | City: | SAN DIEGO |
Market Cap: | 327.0M | IPO Year: | 2015 |
Target Price: | $18.60 | AVG Volume (30 days): | 1.6M |
Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.86 | EPS Growth: | N/A |
52 Week Low/High: | $1.42 - $4.66 | Next Earning Date: | 03-13-2025 |
Revenue: | $235,000 | Revenue Growth: | -33.43% |
Revenue Growth (this year): | 1387.23% | Revenue Growth (next year): | 873.22% |
ATYR Breaking Stock News: Dive into ATYR Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
GlobeNewswire
7 days ago
GuruFocus.com
19 days ago
GlobeNewswire
19 days ago
GlobeNewswire
20 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
The information presented on this page, "ATYR aTyr Pharma Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.